Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 849 | 112 | 726 |
| Samples | 412 | 71 | 336 |
| Peptides | 335 | 44 | 295 |
Function
FBXO11 · F-box protein 11
This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. It can function as an arginine methyltransferase that symmetrically dimethylates arginine residues, and it acts as an adaptor protein to mediate the neddylation of p53, which leads to the suppression of p53 function. This gene is known to be down-regulated in melanocytes from patients with vitiligo, a skin disorder that results in depigmentation. Polymorphisms in this gene are associated with chronic otitis media with effusion and recurrent otitis media (COME/ROM), a hearing loss disorder, and the knockout of the homologous mouse gene results in the deaf mouse mutant Jeff (Jf), a single gene model of otitis media. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jun 2010].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 322 amino-acid changes on canonical ENST00000403359 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FBXO11 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FBXO11 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 6/71 8% |
| Burkitts Lymphoma | 3/32 9% | 16/196 8% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 16/612 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 17/810 2% |
| Colorectal Carcinoma | 13/143 9% | 50/3239 2% |
| Melanoma | 5/210 2% | 29/1899 2% |
| Gastric Carcinoma | 2/74 3% | 20/1809 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 11/1390 1% |
| Bladder Carcinoma | 0/58 0% | 10/956 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 15/1592 1% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Esophageal Carcinoma | 1/23 4% | 5/769 1% |
| Hepatocellular Carcinoma | 0/46 0% | 17/2210 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Breast Carcinoma | 0/144 0% | 23/3264 1% |
| Ovarian Carcinoma | 1/109 1% | 6/998 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 14/2550 1% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Non-Cancerous | 3/104 3% | 2/830 0% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Other Blood Cancers | 2/61 3% | 11/2725 0% |
Mutation Distribution
Where FBXO11 is mutated · all tissues, split by cell line vs tissue
How many mutations in FBXO11 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 849 mutations in FBXO11
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|